The outcome is now the measure.
Own it, or be measured by it.
For a decade, orthopaedic quality was scored on complications and utilization — things that happen in your building, on your clock. That is over. CMS now scores you on what the patient reports a year later, from home, where you cannot see. The measure moved to the one place your OR skill cannot reach.
This is a payment-tied rule, not a best practice.
The CMS THA/TKA PRO-PM — the patient-reported outcome performance measure for total hip and knee replacement — is finalized, and it arrives on two clocks. The specifics are the whole story:
The 50% response rate is the hard part, and it is not a paperwork problem. The year after a joint replacement happens at home, across months no episode of care observes. Getting a patient to answer a survey at month twelve is the same problem as knowing whether they did their rehab — a monitoring problem, not a clerical one. Whoever solves the follow-up owns the score.
Compliance is unavoidable. Ownership is a decision.
Every practice will comply somehow. The real fork is who ends up holding the evidence. Because the same data the government requires is the most valuable thing your practice produces: a longitudinal, structured record of what your care actually does to real patients across your real mix of cases.
A registry or vendor collects the minimum CMS requires, keeps it, and hands you a compliance checkmark. The evidence about your own patients lives on someone else’s server, answering someone else’s question, priced by someone else. You did the work and generated the data. You do not own what it becomes.
The same collection, captured as a byproduct of your workflow, in a record you hold. You clear the mandate and keep a growing evidence base you can use — to counsel patients with your own recovery curves, to compare products and protocols honestly, to show a payer what your care is worth. Compliance becomes an asset instead of a cost.
This is the same distinction a group of surgeons named when they built the OREF/RegenMed MOTIV real-world-evidence network: physicians should not be “treated merely as data sources for institutions, payers, vendors, or registries far removed from the patient’s bedside.” We agree, completely. SurgeonValue is built to sit on the surgeon’s side of that line — the instrument, not the extractor. Physician-led evidence networks and a practice’s own outcome record are the same movement, and they feed each other.
We will not tell you this improves your outcomes.
It would be easy copy and it would be a lie. This year’s RASKAL trial — the first properly powered head-to-head — found robotic knee replacement no better than ordinary navigation on patient-reported outcomes at two years, despite better alignment, shorter operative time, and 82% surgeon preference, at a higher cost per case. Better technical execution did not move what the patient reported. The field is full of tools that improved the process and promised the outcome.
Then, in September 2026, the largest masked randomized trial of robotic knee replacement yet — RACER-Knee in The Lancet, ten hospitals, 33 surgeons, 339 patients, sham incisions so nobody knew their arm — found the same thing at scale: the robot hit its planned alignment more precisely and moved the Forgotten Joint Score by nothing (−1.5 points, confidence interval excluding any meaningful difference), at roughly £1,000 more per case. One detail is the whole lesson: patients who believed they had the robot reported far better scores whichever arm they were in. Unmasked outcome claims measure marketing. Masked ones measure medicine.
Orthopaedics learned this lesson twenty years before the surgical robot trials. Gait laboratories could prove a postoperative foot or ankle was mechanically capable of ambulation, yet miss that pain kept the patient from leaving home — while legacy hybrid scores like the AOFAS rating scale failed reliability and validity testing and static questionnaires fatigued patients before the visit began (Baumhauer, NEJM 2017). As Fabrizio Billi puts it in his critique of single-scalar biomedical benchmarks (Causal of What? When the Benchmark Defines the Disease, Oct 2026), “the laboratory has no stairs”: “cartilage in a dish does not climb stairs after a long day at work. The person carrying it does.” An osteoarthritis intervention that improves an isolated tissue or imaging surrogate while the patient still struggles on the stairs answers a different question than biomechanical rehabilitation that restores stair-climbing without reversing tissue appearance. Modern outcome architecture pairs low-burden, validated instruments (NIH PROMIS Computerized Adaptive Tests anchored on a population T-score of 50 with a standard deviation of 10, alongside joint-specific KOOS JR and HOOS JR) with closed-loop clinical context — connecting postoperative wearable kinematics, surgical alignment, and longitudinal PROs at the point of care (Billi & Bini, JBJS Feb 2026) rather than collapsing recovery into a single retrospective surrogate.
So we are precise. SurgeonValue does not improve your outcome. It captures it, at the response rate CMS requires, and lets you own the evidence. Whether the number then goes up is your medicine, your protocols, your judgment. Our job is to make sure that when the patient answers at month twelve, the answer reaches you — and stays yours.
Collection as a byproduct of the visit.
Pre-op capture at the point of care, then the follow-up that actually closes the loop: the patient tracks recovery from their own phone through the year, which is both the PRO-PM window and a Medicare-reimbursed remote-monitoring stream. The survey that satisfies the mandate and the data that gets you paid for watching the recovery are the same touchpoints. Your live response rate and results sit in your PROM dashboard.
Sourcing. The measure runs as two distinct programs — the inpatient version in Hospital IQR (FY2028) and a separate outpatient/ASC version in Hospital OQR that phases to mandatory in 2031 (FY2032), with a 45% ASC threshold. Timelines, KOOS JR/HOOS JR instruments and response thresholds are from CMS IQR/OQR program materials and the QualityNet THA/TKA measure pages; the two clocks are easy to conflate, so confirm the specifics for your setting against CMS directly before relying on any date. RASKAL: MacDessi et al., Bone & Joint Journal, 2026. RACER-Knee: Parsons et al., The Lancet, 2026. PRO epistemology & PROMIS CAT: Baumhauer & Nawoczenski, Foot & Ankle International, 2006; Bozic & Baumhauer, Clinical Orthopaedics and Related Research, 2016; Baumhauer, New England Journal of Medicine, 2017 (doi:10.1056/NEJMp1702978). Agentic orthopaedics & phenotypic framing: Billi & Bini, Journal of Bone and Joint Surgery, Feb 2026 (“The Application of Agentic Artificial Intelligence in Orthopaedics”, doi:10.2106/JBJS.25.01497); Billi, “Causal of What? When the Benchmark Defines the Disease”, LinkedIn, 14 Oct 2026; Margolis, Schmiedmayer, Huang et al., “DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists”, arXiv:2610.09558, Oct 2026 (preprint). MOTIV: Mercuri & Wickline, Journal of Orthopaedic Experience & Innovation, 2026. This page is general information, not legal, billing, or regulatory advice.